Canaccord lowered the firm’s price target on Nevro (NVRO) to $4 from $7 and keeps a Hold rating on the shares. Canaccord said they are bullish on the Med-Tech sector heading into 2025 as they expect investor interest to increase given smid-cap valuations continue to remain depressed while M&A has picked up and the IPO market seems to have opened. They highlight how AI is changing the space and are seeing continued interest in value-based care in the US, and believe that med-tech is well positioned to help drive the trend for improving patient outcomes while also reducing overall costs.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO:
- Nevro resumed with an Equal Weight at Wells Fargo
- Nevro downgraded to Underweight from Equal Weight at Morgan Stanley
- Nevro announces publication of new data on Nevro1 SI Joint Fusion System
- Nevro Corp. Reports Strong Q3 2024 Financial Performance
- Nevro Corp’s Market Cap Challenges: Impairment Risks and Investor Concerns